Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 7/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3604680 | 1.00 | CHRM1 (0.51) | CHRM1CHRM2CHRM3KMT2AL3MBTL1 | |
| SCHEMBL10077625 | 1.00 | CHRM1 (0.51) | CHRM1CHRM2CHRM3KMT2AL3MBTL1 | |
| SCHEMBL21794034 | 1.00 | CHRM1 (0.51) | CHRM1CHRM2CHRM3KMT2AL3MBTL1 | |
| SCHEMBL16876696 | 0.86 | KMT2A (0.44) | KMT2AL3MBTL1STSGPR119KEAP1 | |
| SCHEMBL3041968 | 0.86 | CHRM1 (0.47) | CHRM1CHRM2CHRM3CHRM4CHRM5 | |
| SCHEMBL757682 | 0.84 | CETP (0.51) | KMT2AL3MBTL1STSGPR119KEAP1 | |
| SCHEMBL9885647 | 0.84 | CETP (0.51) | KMT2AL3MBTL1STSGPR119KEAP1 | |
| SCHEMBL757683 | 0.84 | CETP (0.51) | KMT2AL3MBTL1STSGPR119KEAP1 | |
| SCHEMBL1154130 | 0.83 | KMT2A (0.55) | CHRM1CHRM2CHRM3KMT2AL3MBTL1 | |
| SCHEMBL12668799 | 0.82 | KMT2A (0.56) | CHRM1CHRM2CHRM3KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1192952-A2 | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-04-03 | — | — | EP | claimed |
| US-20110039822-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2011-02-17 | — | — | US | disclosed |
| US-20110039822-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2011-02-17 | — | — | US | disclosed |
| US-7879844-B2 | useful for treating or preventing diseases caused by undesirable cytokine signal transmission such as autoimmune diseases, inflammatory diseases, allergies, transplant rejection, multiple sclerosis, arthritis, psoriasis, asthma, dermatitis, Alzheimer's disease, atherosclerosis, cancer and leukemia | ASTELLAS PHARMA INC. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-7879844-B2 | useful for treating or preventing diseases caused by undesirable cytokine signal transmission such as autoimmune diseases, inflammatory diseases, allergies, transplant rejection, multiple sclerosis, arthritis, psoriasis, asthma, dermatitis, Alzheimer's disease, atherosclerosis, cancer and leukemia | ASTELLAS PHARMA INC. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-7790740-B2 | Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflammation | PFIZER INC (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790740-B2 | Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflammation | PFIZER INC (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790740-B2 | Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflammation | PFIZER INC (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100010007-A1 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2010-01-14 | — | — | US | disclosed |
| US-20100010007-A1 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2010-01-14 | — | — | US | disclosed |
| US-20070015788-A1 | N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
| EP-1492789-B1 | TROPANE DERIVATIVES AS CCR5 MODULATORS | PFIZER LTD (GB) | 2006-06-07 | — | — | EP | disclosed |
| EP-0937069-B1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORP (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050131011-A1 | Chemical compounds | PFIZER, INC. | 2005-06-16 | — | — | US | disclosed |
| US-20050107424-A1 | Tropane derivatives useful in therapy | AGOURON PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| US-6855724-B2 | Tropane derivatives useful in therapy | AGOURON PHARMACEUTICALS, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040014742-A1 | Antiinflammatory agents; viricides | PFIZER INC. | 2004-01-22 | — | — | US | disclosed |
| EP-1192952-A2 | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| US-6051575-A | RESPIRATORY SYSTEM DISORDERS; SKIN DISORDERS; ANTIINFLAMMATORY AGENTS | SCHERING CORPORATION (US) | 2000-04-18 | — | — | US | disclosed |
| US-5968929-A | USEFUL IN THE TREATMENT OF CHRONIC AIRWAY DISEASES SUCH AS ASTHMA | SCHERING CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010007-A1 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | CCR5, CCR2, CXCR3 | CHRM1 324/4885CHRM2 296/4885CHRM3 138/4885 |
| US-20070015788-A1 | N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis | CCR5, CCR2, CX3CR1 | CHRM1 568/4885CHRM2 685/4885CHRM3 251/4885 |
| US-20040014742-A1 | Antiinflammatory agents; viricides | CCR5, CXCR1, CCR1 | CHRM1 251/4885CHRM2 422/4885CHRM3 464/4885 |
| US-20110039822-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | JAK3, JAK1, JAK2 | CHRM1 2596/4885CHRM2 2818/4885CHRM3 1201/4885 |
| US-20050107424-A1 | Tropane derivatives useful in therapy | CCR5, CXCR4, CX3CR1 | CHRM1 53/4885CHRM2 50/4885CHRM3 55/4885 |
| US-20050131011-A1 | Chemical compounds | CCR5, CCR2, CX3CR1 | CHRM1 392/4885CHRM2 417/4885CHRM3 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.